ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial Genetics Investing
Histogenics Announces Top-Line Results From Phase 3 Clinical Trial of NeoCart in Patients With Knee Cartilage Damage Genetics Investing
Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma Biotech Investing
Intellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratory’s Fourth Meeting on Genome Engineering: The CRISPR-Cas Revolution Genetics Investing
HTG Molecular Diagnostics Fulfills First Orders for its Next-Generation Sequencing-Based HTG EdgeSeq Precision Immuno-Oncology Panel Genetics Investing
Nightstar Therapeutics Reports Second Quarter 2018 Financial Results and Business Highlights Genetics Investing